

MAINE STATE LEGISLATURE

The following document is provided by the
LAW AND LEGISLATIVE DIGITAL LIBRARY
at the Maine State Law and Legislative Reference Library
<http://legislature.maine.gov/lawlib>



Reproduced from electronic originals
(may include minor formatting differences from printed original)

STATE OF MAINE
130TH LEGISLATURE
SECOND REGULAR SESSION



Disposition of bills and summaries of all laws enacted or finally passed

**JOINT STANDING COMMITTEE ON HEALTH AND
HUMAN SERVICES**

July 2022

STAFF:

ANNA BROOME, SR. LEGISLATIVE ANALYST
SAMUEL SENFT, LEGISLATIVE ANALYST
OFFICE OF POLICY AND LEGAL ANALYSIS
13 STATE HOUSE STATION
AUGUSTA, ME 04333
(207) 287-1670
<http://legislature.maine.gov/opla/>

MEMBERS:

SEN. NED CLAXTON, CHAIR
SEN. JOSEPH BALDACCI
SEN. MARIANNE MOORE

REP. MICHELE MEYER, CHAIR
REP. MARGARET CRAVEN
REP. ANNE C. PERRY
REP. COLLEEN M. MADIGAN
REP. HOLLY B. STOVER
REP. SAMUEL LEWIS ZAGER
REP. KATHY IRENE JAVNER
REP. ABIGAIL W. GRIFFIN
REP. JONATHAN M. CONNOR
REP. MICHAEL H. LEMELIN

LD 1994 An Act To Establish the Progressive Treatment Program Fund

ENACTED LAW

Public Law 2021, chapter 745 establishes the Progressive Treatment Program Fund as a nonlapsing fund under the administration of the Department of Health and Human Services. The purpose of the fund is to reimburse the legal costs incurred by private entities for initiation and maintenance of progressive treatment programs for legal costs incurred to initiate a progressive treatment program. It requires a private entity seeking reimbursement to submit to the Department of Health and Human Services an itemized bill of legal costs incurred to initiate the progressive treatment program. It limits the amount the department may reimburse a private entity for the legal costs to initiate a progressive treatment program to a maximum of \$800.

LD 2007 An Act To Create the Amyotrophic Lateral Sclerosis Incidence Registry

ENACTED LAW

Public Law 2021, chapter 613 requires health care practitioners and health care facilities to report diagnoses of amyotrophic lateral sclerosis to the Department of Health and Human Services in order for the Maine Center for Disease Control and Prevention to create and maintain a statewide registry for surveillance of the disease in the State. It provides confidentiality protections regarding information that directly or indirectly identifies individual persons. It requires the department to complete annual reports containing statewide prevalence and incidence estimates of amyotrophic lateral sclerosis, including any trends occurring over time across the State.

The law allows the Department of Health and Human Services, Maine Center for Disease Control and Prevention to establish agreements with state, regional and national amyotrophic lateral sclerosis registries for bidirectional data exchange, in a manner consistent with applicable state and federal confidentiality laws and policies. The department may disclose the minimum information necessary to accomplish a specified research purpose only upon successful completion of the research disclosure approval process established by the department and as permitted under applicable human subject research protections, state and federal laws and the department's confidentiality policies and processes. The department shall prepare and submit to the Governor annual reports containing statewide prevalence and incidence estimates of amyotrophic lateral sclerosis, including any trends occurring over time across the State. The reports may not contain any information that directly or indirectly identifies individual persons.